Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jul 17, 2007

Quest to Use Bio-Rad Technology

  • Bio-Rad Laboratories (www.bio-rad.com) inked two transactions with Quest Diagnostics (www.questdiagnostics.com) to place BioPlex® 2200 systems and autoimmune test reagents as well as HIV-1/HIV-2 PLUS O EIA assay. Quest Diagnostics will use the latter to detect HIV-1 and HIV-2 in their network of reference laboratories nationwide. The BioPlex 2200 system is an automated random access testing system employing multiplex technology to simultaneously generate multiple results from a single small patient sample, according to Bio-Rad. In early April, Bio-Rad reported that it had released Epstein Barr Virus kits to run on the BioPlex 2200 system and that it has more than 15 other multiplex reagent kits in development for the system.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »